TONGRENTANGCARE

2667.HK opened lower and continued to decline during the morning session, reaching an intraday low of HKD 2.680 before recovering slightly to close at HKD 2.720, down 5.6% from the previous close of HKD 2.880. This decline extends a recent series of drops, driven by ongoing concerns over growth prospects and valuation, as highlighted in multiple news reports citing falls of over 5% amid growth worries and weak post-IPO performance. Financial data for the latest quarter (Q4 2025) shows EPS fell 50.63% YoY to HKD 0.0211, and net profit dropped 50.63% YoY to approximately HKD 7.54 million, indicating significant deterioration in profitability. The current price of HKD 2.720 is well below the 52-week high of HKD 7.300 (down 62.74%) and below both the 20-day MA (HKD 5.34) and 60-day MA (HKD 5.793), placing it in a historically weak price position. However, the slight rebound from the intraday low suggests some buying interest at lower levels.

Tongrentang Medical Care (2667.HK) slid 5.6% on its trading debut to close at HKD 2.88, opening at HKD 3.05 before trending lower throughout the day. The morning session touched an intraday high of HKD 3.05 but quickly fell to a morning low of HKD 2.89, while the afternoon session saw further weakness to a fresh intraday low of HKD 2.86 before closing at HKD 2.90 on turnover of 1.6455 million shares (turnover rate 0.99%). The decline was driven by valuation concerns combined with weak fundamentals: Q4 2025 net profit plunged 50.63% year-on-year to HKD 7.54 million, operating revenue fell 4.36% to HKD 348.5 million, and net profit margin narrowed to 2.16% from 4.19% a year ago. The stock now trades 60.55% below its 52-week high of HKD 7.30 and significantly below its 20-day MA (HKD 5.57) and 60-day MA (HKD 5.92), indicating persistent price weakness. However, the post-market closing price of HKD 2.90 held above the session's low, suggesting a temporary stabilization of selling pressure.

Beijing Tongrentang Medical Care (2667.HK) opened lower in the morning session and extended losses to as much as 1.6% intraday, before stabilizing near HKD 2.91, eventually closing 4.3% lower at HKD 2.91 — a notable drop from the previous close of HKD 3.04. The stock has been under persistent pressure since its July 7 listing, with today's intraday high of HKD 2.960 failing to reclaim the open level and daily turnover only HKD 151,070, reflecting thin liquidity. The company's Q4 2025 revenue fell 4.36% YoY to HKD 348.5 million, net profit plunged 50.63% YoY to HKD 7.54 million, and EPS was just HKD 0.0211, underlining deteriorating fundamentals. The current price is down over 60% from the 52-week high of HKD 7.3, with the rebound from the 52-week low of HKD 2.62 limited to 11%, and it trades well below both the 20-day MA of HKD 5.783 and 60-day MA of HKD 6.036, signaling extreme weakness. However, reports that Gushengtang is accelerating acquisitions under the Tongrentang umbrella may offer a slim consolidation catalyst.

Beijing Tongrentang Medical Investment Co., Ltd. closed at HKD 2.82 today, up 5.6% from the previous close of HKD 2.67, driven by afternoon buying that pushed the price from HKD 2.65 to the intraday high of HKD 2.80 on 1.476 million shares traded. The stock has lost 61.4% year-to-date and remains 61.4% below its 52-week high of HKD 7.3, though it has rebounded 7.6% from the 52-week low of HKD 2.62. Current price is still well below the 20-day MA of HKD 5.99 and 60-day MA of HKD 6.16, indicating the short-term bounce has not reversed the long-term downtrend. While the company's 909 employees and foundation in 2015 provide a structural backdrop, future earnings will be key to sustaining this uptick.

Beijing Tongrentang Medical Care opened lower in the morning session and continued to decline, at one point falling over 8% before closing at HKD 2.79, down 4.78% from the previous close of HKD 2.93. The stock's weak performance is primarily attributed to continued post-IPO declines, having already fallen about 15% in gray market trading and breaking its issue price on debut. Today's intraday low of HKD 2.78 sits just 0.36% above its 52-week low of HKD 2.78, while it remains 61.78% below its 52-week high of HKD 7.30, trading well below its MA20 (HKD 6.449) and MA60 (HKD 6.49). Financially, Q4 2025 operating revenue of HKD 348.5 million declined 4.36% YoY, net profit of HKD 7.54 million plunged 50.63% YoY, and net profit margin fell from 4.19% to 2.16%, reflecting fundamental weakness coupled with low market sentiment. However, today's volume of only 977,000 shares and a turnover rate of 0.6% indicate limited selling pressure.